 | Up a level |
Clark, Richard E 
ORCID: 0000-0002-1261-3299, Polydoros, Fotios ORCID: 0000-0001-5181-6817, Apperley, Jane F, Milojkovic, Dragana, Pocock, Christopher, Smith, Graeme, Byrne, Jenny L, de lavallade, Hugues, O'Brien, Stephen G, Coffey, Tony et al (show 2 more authors)
(2017)
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.
The Lancet Haematology, 4 (7).
E310-E316.
Clark, Richard E ORCID: 0000-0002-1261-3299, Polydoros, Fotios, Apperley, Jane F, Milojkovic, Dragana, Rothwell, Katherine, Pocock, Christopher, Byrne, Jennifer, de lavallade, Hugues, Osborne, Wendy, Robinson, Lisa et al (show 4 more authors)
(2019)
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
The Lancet Haematology, 6 (7).
E375-E383.
Austin, Gemma M, Knight, Katy, Bell, Joanne, Carter, Anthony, Heartin, Earnest, Watson, David, Foroni, Letizia, Christmas, Stephen E, Polydoros, Fotios and Clark, Richard E ORCID: 0000-0002-1261-3299
(2019)
The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial.
BRITISH JOURNAL OF HAEMATOLOGY, 185 (4).
pp. 791-793.